Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ATOM2: A Randomized Phase II Trial on Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer After Osimertinib Treatment

NCT07379476 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT07379476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07379476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ATOM2: A Randomized Phase II Trial on Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer After Osimertinib Treatment
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 2
Overall status
Recruiting
Start date
February 11, 2026
Completion date
March 3, 2030
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc)